Why Is Ionis Pharmaceuticals (IONS) Stock Down -7.22% Today?
Key Takeaways
- IONS shares fell 7.22% in Thursday's session, extending losses after Wednesday's 23.9% plunge following the CARDIO-TTRansform Phase 3 trial failure.
- The primary catalyst remains the announcement that eplontersen (Wainua) failed to meet its primary endpoint in transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).
- Secondary drivers include analyst price target cuts, downward estimate revisions, and continued repositioning by institutional investors.
- Competitor stocks Alnylam Pharmaceuticals (ALNY) and BridgeBio Pharma (BBIO) rallied sharply as the ATTR-CM competitive landscape consolidates.
- Broader biotech sector indices were mixed, confirming the move is entirely company-specific rather than macro-driven.
- Traders are now watching for the full data presentation at the European Society of Cardiology Congress in August 2026 and any strategic updates from management.
Opening Summary
Shares of IONS, Ionis Pharmaceuticals, Inc., a pioneer in RNA-targeted therapeutics, are down 7.22% in Thursday's trading session, changing hands at $59.63 as of early afternoon. The stock closed the prior session at $64.27, which itself represented a 23.9% collapse from Wednesday's open following the company's disclosure that its pivotal Phase 3 CARDIO-TTRansform trial of eplontersen in ATTR-CM failed to meet its primary efficacy endpoint. Today's continued selling pressure reflects a combination of analyst downgrades, reduced price targets, and the market's ongoing reassessment of Ionis's revenue growth trajectory without the blockbuster ATTR-CM opportunity.
Phase 3 Trial Failure: The Core Catalyst
The overwhelming driver behind the two-day rout in IONS stock is the unexpected failure of the CARDIO-TTRansform study. Ionis and its partner AZN (AstraZeneca) announced on July 9 that the 1,432-patient trial did not demonstrate a statistically significant reduction in the composite endpoint of cardiovascular mortality and recurrent cardiovascular events through Week 140 when eplontersen was added to standard-of-care therapy. The result blindsided Wall Street, where consensus had widely assumed the trial would succeed given the mechanistic similarity between eplontersen and Alnylam's already-approved Amvuttra, which succeeded in its own ATTR-CM pivotal trial.
A critical factor in the failure appears to be the high background use of stabilizer therapies such as Pfizer's Vyndamax. In CARDIO-TTRansform, 57% of patients were on a stabilizer at baseline, and an additional 24% initiated one during the trial—meaning more than 80% of participants received stabilizer therapy alongside the study drug. In the prespecified monotherapy subgroup, eplontersen showed a nominally significant hazard ratio of 0.71, but no treatment effect was observed in patients already receiving stabilizers. This dynamic has fundamentally reset the commercial opportunity for Wainua in ATTR-CM, with peak sales estimates reportedly cut from approximately $6.5 billion to around $4 billion.
Analyst Downgrades and Price Target Cuts
Thursday's additional selling pressure is being amplified by a wave of analyst reactions. Multiple firms issued price target reductions in the wake of the trial readout, with several analysts acknowledging that the failure was not priced into their models. The consensus price target, which stood above $100 prior to the announcement, is now being recalibrated lower as analysts strip ATTR-CM revenue from their financial models. The removal of expected milestone payments from AstraZeneca—potentially several hundred million dollars tied to Phase 3 success and regulatory approvals—further weighs on the near-term earnings outlook.
Competitive Landscape Shift
The CARDIO-TTRansform failure has reshaped the competitive dynamics of the ATTR-CM market, which is estimated to be worth more than $15 billion at peak. With eplontersen now unlikely to enter the cardiomyopathy indication in the near term, the market consolidates around three established players: Pfizer's Vyndamax, Alnylam's Amvuttra, and BridgeBio's Attruby. Shares of ALNY (Alnylam Pharmaceuticals) surged approximately 10% on Wednesday and continued to trade higher Thursday, while BBIO (BridgeBio Pharma) also posted double-digit gains. The removal of a direct nucleic acid-based competitor significantly strengthens the commercial positioning of both companies in the ATTR-CM space.
Market Context and Trading Activity
Trading volume in IONS has been exceptionally elevated. Wednesday's session saw nearly 11 million shares change hands, more than five times the three-month average daily volume of approximately 1.86 million shares. Thursday's volume is also running well above average, indicating that institutional repositioning is still underway. The stock has sliced through multiple technical support levels, including its 50-day and 200-day moving averages, and is now trading at levels last seen in late 2025. The broader Nasdaq Biotechnology Index was relatively flat, underscoring that the move is entirely company-specific. The S&P 500 and Dow Jones Industrial Average were modestly lower, providing no meaningful macro tailwind or headwind.
Trending AI Robots
In volatile market environments like the one currently affecting biotech stocks, traders often turn to automated strategies to navigate sharp price swings. Tickeron's Trending AI Robots page features a curated selection of AI-powered trading bots that have demonstrated strong performance under current market conditions. With hundreds of bots covering thousands of tickers across multiple strategies and timeframes, the platform highlights only those algorithms that are currently delivering the most robust results. Each bot varies by strategy type, performance metrics, and the symbols it trades, allowing users to identify approaches aligned with their objectives. Explore the Trending AI Robots page to see which strategies are resonating in today's market.
What Comes Next for IONS
The immediate focus for IONS investors shifts to the full CARDIO-TTRansform dataset, which Ionis and AstraZeneca plan to present at the European Society of Cardiology Congress in August 2026. That presentation will provide granular detail on secondary endpoints, biomarker data, and subgroup analyses that could inform whether a narrower regulatory pathway—potentially in stabilizer-intolerant or stabilizer-inadequate patients—remains viable. Beyond Wainua, attention will turn to Ionis's wholly owned commercial portfolio, including the recent launches of TRYNGOLZA (olezarsen) and DAWNZERA (donidalorsen), as well as the pivotal REVEAL Phase 3 trial of obudanersen in Angelman syndrome. Management has reiterated its target of achieving cash flow breakeven by 2028, a milestone that now depends more heavily on the success of these internal programs. Risks include the possibility that the ATTR-CM opportunity is permanently foreclosed, further analyst downgrades, and execution risk across the remaining pipeline.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
IONS's RSI Oscillator ascends from oversold territory
The RSI Oscillator for IONS moved out of oversold territory on August 03, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 26 similar instances when the indicator left oversold territory. In of the 26 cases the stock moved higher. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on August 07, 2026. You may want to consider a long position or call options on IONS as a result. In of 102 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for IONS just turned positive on August 03, 2026. Looking at past instances where IONS's MACD turned positive, the stock continued to rise in of 52 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where IONS advanced for three days, in of 277 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 212 cases where IONS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 9 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IONS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
IONS broke above its upper Bollinger Band on August 19, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. IONS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock slightly better than average.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (22.573) is normal, around the industry mean (20.145). P/E Ratio (0.000) is within average values for comparable stocks, (22.992). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.861). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (11.148) is also within normal values, averaging (444.692).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of antisense drugs
Industry Biotechnology
Advertisement